Pharmacotherapy for pancreatic cancer: Difficulties and prospects

VernacularTitle: 胰腺癌药物治疗的现状与困境
Author: Zhenghang WANG ¹ ; Jun ZHOU ¹ ; Lin SHEN ¹
Author Information

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology of Clinical School of Oncology, Peking University Beijing Cancer Hospital & Beijing Institute for Cancer Research, Beijing 100142, China
Publication Type:Journal Article
Keywords: Pancreatic neoplasms; Biological characteristics; Systemic pharmacotherapy; Prospects
From: Chinese Journal of Oncology 2017;39(9):712-716
CountryChina
Language:Chinese
Abstract: The incidence of pancreatic cancer has been obviously increasing in China over the last decade, however, those patients with advanced pancreatic cancer are suffering from limited treatment strategies and poor clinical prognosis. Chemotherapy improved the overall survival of cases with advanced pancreatic cancer to 8-11 months, and erlotinib brought an additional survival of only 10 days. In this article, the recent progresses on advanced pancreatic cancer were reviewed at the genetic and molecular sub-typing levels, and corresponding clinical transformation studies summarized, some of which have showed encouraging clinical prospects but others have failed due to the complexity of pancreatic cancer. By learning from experiences in the successful therapeutic strategies and lessons from the failed cases, we hope to optimize future clinical research from bedside to bench.